|AZ 960JAKs inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Description||AZ 960 is a potent, selective and ATP competitive inhibitor of JAK2 with Ki value of 0.45 nM.|
|IC50||0.45 nM (Ki)|
|Cas No.||905586-69-8||SDF||Download SDF|
|Solubility||Soluble in DMSO > 10 mM||Storage||Store at -20°C|
AZ960 is a novel inhibitor of janus-associated kinases (JAKs) that exhibits a potent inhibition against janus kinase 2 (JAK2) with the value of inhibition constant of Ki of 0.45 nmol/L. It also exhibits a lesser inhibitory effects against other JAKs family members, including JAK1, JAK3 and TYK2 as well as other kinases, including TrkA, Aurora A and FAK, with 50% inhibition concentration IC50 of around 0.1 μmol/L. In recent studies, AZ960 demonstrates potential anti-cancer activity against adult T-cell leukemia (ATL), an aggressive malignancy of CD4+ T lymphocytes, by effectively inducing growth arrest and apoptosis in human T-cell lumphotropic virus type 1 (HTLV-1) infected T cells.
Yang J, Ikezoe T, Nishioka C, Furihata M, Yokoyama A. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther. 2010;9(12):3386-3395.